A Multi-Center, Global, Open-Label, Phase 1b/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma As Well As to Evaluate the Safety and Efficacy of Intravenous Brincidofovir in Patients With Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma Using The Recommended Phase 2 Dose

This study is a multi-center, global, open-label, Phase 1b/2 clinical study, and it will be conducted at multiple study sites in several countries, including Japan, Korea, and Singapore, to reveal the safety, tolerability, dose limiting toxicity (DLT), maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D), pharmacokinetics (PK), and preliminary efficacy of BCV in patients with relapsed or refractory lymphoma and to assess the efficacy and safety of Brincidofovir (SyB V-1901, BCV) in patients with relapsed or refractory Extranodal Natural Killer/T-cell Lymphoma (ENKL).
This study consists of 2 parts and will enroll a total (maximum) of 43 male and female participants who meet the eligibility criteria (Phase 1b part: Up to 18 participants [3 to 6 participants in each of the 3 cohorts], Phase 2 part: 25 participants).

Start Date09 Jun 2025

Sponsor / Collaborator

SymBio Pharmaceuticals Ltd.

NCT05935917

/ CompletedPhase 1

A Phase 1, Open-label, Single-dose, Randomized, Two-period, Crossover Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adult Participants

The goal of this clinical trial is to evaluate whether both Form H and Form II, 100mg brincidofovir tablets are bioequivalent, when given under fasting conditions in healthy adults.
Participants will be randomized to each receive one tablet of Form H and one tablet of Form II,14 days apart and undergo pharmacokinetic testing pre-dose and post-dose to evaluate safety. This is an open-label, single-dose, randomized, two-period, crossover study.

Start Date30 May 2023

Sponsor / Collaborator

Emergent BioSolutions, Inc.

NCT05511779

/ TerminatedPhase 2

Phase II, Open-label, Randomized, Multiple Ascending Dose Confirmation of the Safety and Tolerability of Brincidofovir in Subjects With BK Virus Infection (Viremia) After Kidney Transplantation (BASTION)

This is a Phase II, multicenter, open-label, randomized, standard of care (SOC) controlled, multiple ascending dose study to assess the safety and tolerability of IV Brincidofovir (BCV) in subjects with BKV infection after kidney transplantation. The study will be conducted at multiple study sites in several countries including Australia and Japan. Subjects who meet eligibility criteria will be enrolled in the study and will be randomized and assigned to BCV or SOC (defined as use of the same immunosuppressant administered during prescreening) before receipt of the first dose of study drug in both the Dose Escalation Phase and the Expansion Phase.

Start Date14 Oct 2022

Sponsor / Collaborator

SymBio Pharmaceuticals Ltd.

100 Clinical Results associated with Brincidofovir

100 Translational Medicine associated with Brincidofovir

100 Patents (Medical) associated with Brincidofovir

512

Literatures (Medical) associated with Brincidofovir

31 Dec 2025·Virulence

Mpox: Global epidemic situation and countermeasures

Review

Author: Luo, Yinghua ; Jin, Chenghao ; Hou, Wenshuang ; Tang, Yanjun ; Wu, Nan ; Liu, Yanzhi ; Quan, Quan

Mpox, is a zoonotic disease caused by the monkeypox virus and is primarily endemic to Africa. As countries gradually stop smallpox vaccination, resistance to the smallpox virus is declining, increasing the risk of infection with mpox and other viruses. On 14 August 2024, the World Health Organization announced that the spread of mpox constituted a public health emergency of international concern. Mpox's transmission routes and symptoms are complex and pose new challenges to global health. Several vaccines (such as ACAM2000, JYNNEOS, LC16m8, and genetically engineered vaccines) and antiviral drugs (such as tecovirimat, brincidofovir, cidofovir, and varicella immunoglobulin intravenous injection) have been developed and marketed to prevent and control this disease. This review aims to introduce the epidemic situation, epidemiological characteristics, physiological and pathological characteristics, and preventive measures for mpox in detail, to provide a scientific basis for the prevention and control of mpox viruses worldwide.

01 Aug 2025·BIOLOGICALS

A comprehensive review of current diagnostic techniques for Monkeypox virus detection

Review

Author: Benani, Abdelouaheb ; Madihi, Salma

Monkeypox (Mpox) is an infectious disease caused by the Monkeypox virus (MPXV), initially confined to Central and Western Africa, but now spreading globally. The clinical manifestations are often atypical in the current Mpox outbreak, in addition to the critical challenges in MPXV typing and the difficulty in reliably distinguishing between clades. Therefore, diagnosing Mpox based on clinical signs and symptoms only can be challenging. Current treatment is not specific to MPXV and primarily involves supportive care and antiviral drugs that inhibit viral DNA synthesis, such as Tecovirimat and Brincidofovir. This review provides a comprehensive overview of current laboratory techniques for MPXV detection, encompassing both direct and indirect diagnostic methods. It highlights recent advancements, evaluates the strengths and limitations of each approach, and proposes innovative strategies to enhance global diagnostic capabilities, including the potential roles of computational drug discovery and immunoinformatics in designing multi-epitope vaccines targeting MPXV and its variants. The most effective measure to control MPXV spread remains vaccination, timely diagnosis, isolation of infected individuals, maintaining personal hygiene, and avoiding contact with contaminated persons, objects, and animal waste.

04 Jun 2025·CLINICAL INFECTIOUS DISEASES

Fatal Borealpox in an Immunosuppressed Patient Treated With Antivirals and Vaccinia Immunoglobulin—Alaska, 2023

Article

Author: McCollum, Andrea M ; Hutson, Christina ; Davidson, Whitni ; Doty, Jeffrey B ; Tuttle, Alexandra ; Deng, Jiusheng ; Townsend, Michael B ; Satheshkumar, Panayampalli S ; McLaughlin, Joseph B ; Wilkins, Kimberly ; Castrodale, Louisa J ; Smith, Lisa ; Venkatasubrahmanyam, Shivkumar ; Noll, Nicholas ; Villalba, Julian A ; Parker, Jayme ; Westley, Benjamin ; Mego, Thomas ; Rao, Agam K ; Park, Sarah Y ; Carson, William C ; Bercovici, Sivan ; Laurance, John ; Newell, Katherine G ; Bhatnagar, Julu ; Li, Yu ; Gigante, Crystal M ; Reagan-Steiner, Sarah ; Rogers, Julia H

Abstract:

Background:

Borealpox virus (BRPV, formerly known as Alaskapox virus) is a zoonotic member of the Orthopoxvirus genus first identified in a person in 2015. In the 6 patients with infection previously observed, BRPV involved mild and self-limiting illness. We report the first fatal BRPV infection in an immunosuppressed patient.

Methods:

A man aged 69 years from Alaska's Kenai Peninsula was receiving anti-CD20 therapy for chronic lymphocytic leukemia. He presented to care for a tender, red papule in his right axilla with increasing induration and pain. The patient failed to respond to multiple prescribed antibiotic regimens and was hospitalized 65 days after symptom onset for progression of presumed infectious cellulitis. BRPV was eventually detected through orthopoxvirus real-time polymerase chain reaction testing of mucosal swabs. He received combination antiviral therapy, including 21 days of intravenous tecovirimat, intravenous vaccinia immunoglobulin, and oral brincidofovir. Serial serology was conducted on specimens obtained posttreatment initiation.

Findings:

The patient's condition initially improved with plaque recession, reduced erythema, and epithelization around the axillary lesion beginning 1 week posttherapy. He later exhibited delayed wound healing, malnutrition, acute renal failure, and respiratory failure. He died 138 days after symptom onset. Serologic testing revealed no evidence the patient generated a humoral immune response. No secondary cases were detected.

Conclusions:

This report demonstrates that BRPV can cause overwhelming disseminated infection in certain immunocompromised patients. Based on the patient's initial response, early BRPV identification and antiviral therapies might have been beneficial. These therapies, in combination with optimized immune function, should be considered for patients at risk for manifestations of BRPV.

News (Medical) associated with Brincidofovir

06 Mar 2025

·medcitynews.com

First-in-Class Brain Cancer Drug Strikes a Chord With Jazz Pharma to the Tune of a $935M M&A Deal - MedCity News

Brain cancers are notoriously difficult to treat, with surgery and radiation continuing to be the main options for these malignancies. A rare and aggressive type of brain tumor driven by a particular genetic signature could soon have its first approved drug treatment. Jazz Pharmaceuticals is now committing $935 million to add this prospect to its pipeline. The drug, dordaviprone, was developed by Durham, North Carolina-based Chimerix. The cancer is H3 K27M-mutant diffuse glioma, a high-grade glioma that affects children and young adults. While surgery is a treatment option for brain cancers, it’s usually risky for H3 K27M gliomas because these tumors affect critical parts of the brain and spinal cord. Meanwhile, radiation introduces complication risks and is not curative. “This is a very high unmet need,” Jazz Chief Medical Officer Robert Iannone said, speaking during the company’s presentation Wednesday at TD Cowen’s annual health care conference in Boston. “I’m a pediatric oncologist by training. There really has been no progress in this area. I know from treating these patients, it’s been a very sad situation to have only radiation and surgery as the effective therapy.” Sponsored Post Tackling Messy Provider Data with an NPI-Forward Approach Mike Wirth of ProviderTrust shares insights about the company in this interview at the ViVE 2025 conference in Nashville last month. By ProviderTrust and MedCity News About 2,000 patients are affected by H3 K27M-mutant gliomas annually in the U.S., according to a Chimerix estimate. Dordaviprone is part of a new class of cancer drugs called imipridones. These small molecules target certain G protein-coupled receptors and enzyme targets, altering their activity to lead to cancer cell death. Dordaviprone, known earlier in its development as ONC201, is designed to selectively target mitochondrial protease ClpP and dopamine receptor D2. Phase 2 results showed tumor regression in patients with glioblastoma who exhibited the H3 K27M mutation. In the 50 patients included in the primary efficacy analysis, Chimerix reported a 28% objective response rate and a median duration of response of 10.4 months. A Phase 3 test enrolling patients newly diagnosed with this type of brain cancer could support first-line use of the drug; interim results are expected in the third quarter of 2025. But based on the Phase 2 data, Chimerix is seeking accelerated approval of dordaviprone for recurrent H3 K27M-mutant diffuse glioma. Last month, the FDA accepted the new drug application under priority review, setting an Aug. 18 target date for a regulatory decision. Though cancer is the therapeutic focus of Chimerix, it’s a relatively new area for the company, one of the older biotechs in North Carolina’s Research Triangle. Dordaviprone came from Chimerix’s 2021 cash and stock acquisition of Oncoceutics, a clinical-stage developer of imipridones. Besides the lead drug candidate, the deal also brought ONC206, an imipridone that Chimerix has advanced to Phase 1 testing in central nervous system tumors. Per terms of the Oncoceutics acquisition, that company’s shareholders could receive up to $360 million in milestone payments plus royalties from sales. Chimerix, founded in 2000, began as an antiviral drug developer. For most of the biotech’s history, its focus was brincidofovir, a molecule initially developed for treating cytomegalovirus infection. It failed in that indication, but won FDA approval in 2021 as a treatment for smallpox and is now known by the brand name Tembexa. In 2022, Chimerix sold that drug’s rights to Emergent BioSolutions for $225 million up front and up to $100 million in milestone payments. Chimerix applied the cash toward clinical development of dordaviprone in brain cancer. Sponsored Post Webinar: Tips To Have Your Practice Succeed This Year This on-demand webinar will offer insights and share tips on helping practices run more efficiently. By Elation Health and MedCity News In the past year, Chimerix’s stock price has mostly traded below the $1 mark. Those shares got a significant lift in December after the biotech announced it would seek accelerated approval for dordaviprone. According to acquisition terms disclosed Wednesday, Dublin-based Jazz will pay $8.55 in cash for each Chimerix share, representing a 72% premium to the biotech’s closing stock price on Tuesday. There’s potential for additional financial upside. Because Chimerix’s drug is under priority review, it’s eligible for a rare pediatric disease priority review voucher if the drug is approved. Such vouchers are typically sold to big pharma companies, and they once fetched prices in the range of $100 million. Recent voucher sales have been in the neighborhood of $150 million. The Jazz portfolio currently has five cancer drugs. Chief Financial Officer Philip Johnson described dordaviprone as a “great fit with our oncology business,” adding that the drug can leverage Jazz’s commercial capabilities and offers a patent life extending into 2037 and potentially longer. The Chimerix acquisition fits Jazz’s strategy of acquiring assets for rare opportunities in niche markets, Leerink Partners analyst Marc Goodman wrote in a note to investors. Beyond addressing a high unmet medical need, the deal leverages Jazz’s expertise in rare diseases and oncology. Jazz prefers acquiring late-stage assets that have a potential near-term commercial launch, Goodman said. Leerink is still researching the H3 K27M market opportunity, but he noted that given the size of the patient population for this ultra-rare type of cancer, it makes sense for dordaviprone to fall within the $300,000 to $800,000 price range for orphan drug products. The acquisition has been approved by the boards of both Jazz and Chimerix, but still must meet customary closing conditions including the tender of the majority of the outstanding shares of Chimerix. The companies expect the deal to close in the second quarter of this year.

Clinical ResultAcquisitionPhase 2Phase 3Priority Review

16 Jan 2025

·www.globenewswire.com

Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)

ADDIS ABABA, Ethiopia and KINSHASA, Democratic Republic of the Congo and WASHINGTON and PARIS, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Africa CDC’s support for the MOSA, a pan-African randomized platform adaptive trial for the MpOx Study, adding to the initial EU funding, has enabled the enrollment of the first patients at Mbandaka Hospital in Equateur Province, Democratic Republic of Congo (DRC). These patients have been randomized in this pivotal clinical trial, marking a critical step in addressing the Mpox health threat. As Clade Ib cases emerge outside Africa and Clade I and II cases continue to be reported across the continent, Africa CDC, INRB, and PANTHER are leading efforts to test promising therapeutic options to combat this persistent health threat. Declared a Public Health Emergency of Continental Security on August 13, 2024, Mpox remains a significant health threat across Africa, particularly among vulnerable populations such as women, children, and individuals living with HIV. Despite the pressing need, no therapeutic has been approved to treat Mpox in the United States or Africa. Recent results from the PALM 007 and STOMP studies showed that tecovirimat did not show the expected effect on lesion resolution, underscoring the need for additional therapeutic options. The MOSA trial demonstrates Africa’s leadership in addressing this urgent healthcare gap. The study will evaluate different antivirals, either alone or in combination. It will start by evaluating the safety and efficacy of brincidofovir. Brincidofovir is an antiviral from the global life sciences company Emergent BioSolutions. In the United States it is available under a single-patient emergency use Investigational New Drug (IND) for Mpox. The safety and efficacy of brincidofovir to treat Mpox in humans has not been established in double-blind, placebo-controlled studies for Mpox. In the MpOx Study, patients will receive either brincidofovir or a matching placebo in a liquid oral formulation, administered once-a-week, for 2 weeks. A first interim analysis is expected by the end of Q1 2025. “Africa is not just responding to the Mpox outbreak; we are leading the charge in finding solutions by spearheading research and development for Mpox therapeutics,” said Africa CDC Director General, Dr. Jean Kaseya. “The MpOx Study represents a groundbreaking step toward developing a treatment. This effort goes beyond research—it’s about African ownership and leadership in addressing our continent's health challenges through vital, innovative research.” Sponsored by PANTHER, a key research partner of Africa CDC, the MOSA trial builds upon initial funding provided by the European Union’s Horizon Europe program. The study protocol was reviewed through the AVAREF collaborative process in 2023, ensuring it meets the highest ethical and scientific standards. The innovative study design includes pre-planned interim analyses, allowing for rapid decision-making should early signs of either futility or success be observed. “This milestone highlights the vital role of research preparedness and response. Funded initially by Horizon Europe as part of the emergency response to the mpox outbreak in 2022, I am delighted to see MOSA trial fully operational now to advance treatments for mpox.” Marc Lemaître, European Commission, Director-General for Research and Innovation. “We are proud of this important milestone illustrating PANTHER’s mission in addressing continental epidemic priorities,” said Prof. Samba Ousmane Sow, Director General of the Centre for Vaccine Development in Mali (CVD-Mali) and President of the Board of PANTHER. “We hope to contribute to Africa CDC’s response to the current crisis while also deriving concrete lessons to better prepare for future ones.” As Africa continues to report rising Mpox cases, particularly in the DRC, the MOSA trial seeks to provide critical data on potential treatment options. The study will recruit both children and adults, focusing on those most at risk of severe outcomes, especially in remote areas. “We look forward to advancing MOSA, another critical research project that complements ongoing studies on transmission, vaccines and social sciences,” said Prof Placide Mbala, Principal Investigator for the study in the DRC and Head of the Department of Epidemiology and Global Health at INRB. “Mpox continues to be a global threat to public health, creating a need for treatments and vaccines,” said Simon Lowry, M.D., chief medical officer, head of research and development, Emergent. “We applaud Africa CDC and PANTHER for their work progressing the ‘MpOx Study in Africa’ (MOSA) and advancing research for brincidofovir.” The U.S. FDA Prescribing Information for TEMBEXA® (brincidofovir) is provided for additional safety information here. About the Pandemic Preparedness Platform for Health and Emerging Infections Response (PANTHER) PANTHER is the first African-led pandemic preparedness platform for health and emerging infection response. Bringing together leading African and global researchers and public health teams, it aims to create regional hubs and clinical research platforms to support preparedness and rapid response to emerging infectious diseases globally, particularly in Africa. For more information, visit https://pantherhealth.org. PANTHER is sponsoring MOSA as part of the MPX-RESPONSE Project that has received funding from the European Union’s Horizon Europe Research and Innovation programme under grant agreement 101115188 About Africa Centres for Disease Control and Prevention (Africa CDC)The Africa Centres for Disease Control and Prevention (Africa CDC) is a public health agency of the African Union. It is autonomous and supports member states in strengthening health systems. It also helps improve disease surveillance, emergency response, and disease control. Learn more at: http://www.africacdc.org and connect with us on LinkedIn, Twitter, Facebook and YouTube. About Emergent BioSolutions At Emergent, our mission is to protect and enhance life. For over 25 years, we’ve been at work defending people from things we hope will never happen—so we are prepared just in case they ever do. We provide solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that we develop and manufacture for governments and consumers. We also offer a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers. To learn more about how we help protect public health, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify. Media Contacts: Margaret Edwin | Director of Communication and Public Information | Africa CDC EdwinM@africacdc.org Jessica Ilunga | Communication Officer | PANTHEREmail: Media@pantherhealth.orgWebsite: www.pantherhealth.orgTwitter | LinkedIn Assal Hellmer | Vice President, Communications | Emergent BioSolutions Email: mediarelations@ebsi.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/683aea7c-60d3-4af9-8964-1d0031f84727

Clinical StudyVaccine

06 Nov 2024

·www.globenewswire.com

Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa

PANTHER to conduct clinical trial under the leadership of Africa Centres for Disease Control and Prevention GAITHERSBURG, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that brincidofovir (brand name TEMBEXA®) will be included in a clinical trial conducted and sponsored by PANTHER, under the leadership of the Africa Centres for Disease Control and Prevention (Africa CDC), as part of the ‘MpOx Study in Africa’ (MOSA). The study will evaluate the safety and efficacy of brincidofovir in treating mpox virus in a randomized double-blind placebo-controlled trial. “We applaud Africa CDC and PANTHER for the launch of the ‘MpOx Study in Africa’ (MOSA), an important step in advancing research for brincidofovir, and are proud to support the trial with our brincidofovir antiviral treatment,” said Joe Papa, president and CEO, Emergent BioSolutions. “Emergent is committed to working with partners around the world to study and produce vaccines and treatments to address all orthopoxviruses, including mpox and smallpox.” Brincidofovir is an antiviral medical countermeasure that is part of Emergent’s product portfolio. There are currently no therapeutics approved by the FDA to treat patients infected by mpox virus who are at risk of severe complications. While brincidofovir treatment is available to be used for mpox in the U.S. under emergency Investigational New Drug protocol, it has not yet been evaluated in any randomized double-blind placebo-controlled studies for mpox. On August 13, Africa CDC declared mpox a public health emergency of continental security, which was followed by a statement from World Health Organization’s Director-General declaring that the upsurge of mpox in the DRC and a growing number of countries in Africa constitutes a public health emergency of international concern under the International Health Regulations (2005). About the clinical trial: The study MOSA (MpOx Study in Africa) is a pan-African, double-blind, platform adaptive trial assessing treatments for patients diagnosed with mpox virus. Inclusion criteria are children, adults with mucosal lesions or PLWHIV. It is sponsored by PANTHER as part of the MPX-RESPONSE Project that has received funding from the European Union’s Horizon Europe Research and Innovation programme under grant agreement 101115188. The trial is scheduled to begin in the coming weeks in the Democratic Republic of Congo and neighboring countries. Please read full Prescribing Information for TEMBEXA® for additional safety information here. About Emergent BioSolutions At Emergent, our mission is to protect and enhance life. For 25 years, we’ve been at work defending people from things we hope will never happen—so we are prepared just in case they ever do. We provide solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that we develop and manufacture for governments and consumers. We also offer a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers. To learn more about how we help protect public health, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify. Safe Harbor Statement This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding the any future procurements to supply brincidofovir (brand name TEMBEXA®), are forward-looking statements. We generally identify forward-looking statements by using words like “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “should,” “will,” “would,” and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on Emergent’s current intentions, beliefs, and expectations regarding future events. Emergent cannot guarantee that any forward-looking statement will be accurate. Readers should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Emergent’s expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Emergent does not undertake to update any forward-looking statement to reflect new information, events or circumstances. There are a number of important factors that could cause Emergent’s actual results to differ materially from those indicated by any forward-looking statements. Readers should consider this cautionary statement, as well as the risk factors identified in Emergent’s periodic reports filed with the U.S. Securities and Exchange Commission when evaluating Emergent’s forward-looking statements. Investor Contact: Richard S. Lindahl Executive Vice President, CFO lindahlr@ebsi.com Media Contact: Assal Hellmer Vice President, Communications mediarelations@ebsi.com

Clinical Study

100 Deals associated with Brincidofovir

External Link

KEGG	Wiki	ATC	Drug Bank
D10547	Brincidofovir	J05A	DB12151

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Smallpox	United States	Emergent Biodefense Operations Lansing LLC	04 Jun 2021
Smallpox	United States	Emergent BioDefense Operations Lansing, Inc.	04 Jun 2021

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pyelonephritis	Phase 3	United States	Chimerix, Inc.	01 Sep 2015
Adenoviridae Infections	Phase 3	United States	Chimerix, Inc.	01 Mar 2014
Cytomegalovirus viremia	Phase 3	United States	Chimerix, Inc.	01 Aug 2013
Cytomegalovirus viremia	Phase 3	Belgium	Chimerix, Inc.	01 Aug 2013
Cytomegalovirus viremia	Phase 3	Canada	Chimerix, Inc.	01 Aug 2013
Extranodal NK-T-Cell Lymphoma	Phase 2	China	SymBio Pharmaceuticals Ltd.	09 Jun 2025
Extranodal NK-T-Cell Lymphoma	Phase 2	Japan	SymBio Pharmaceuticals Ltd.	09 Jun 2025
Extranodal NK-T-Cell Lymphoma	Phase 2	Singapore	SymBio Pharmaceuticals Ltd.	09 Jun 2025
Kidney Diseases	Phase 2	Japan	SymBio Pharmaceuticals Ltd.	14 Oct 2022
Hemorrhagic Fever, Ebola	Phase 2	-	Chimerix, Inc.	01 Oct 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASH2024	Not Applicable	Non-Hodgkin Lymphoma	-	Brincidofovir	mqotgnkpws(dzxvwpbalh) = jjapicvfjh fqsskashve (armubvbixb )	-	09 Dec 2024
EHA2024	Not Applicable	Peripheral T-Cell Lymphoma	-	Brincidofovir	omdkpyjbwi(iomzcwbdeo) = bknxyvmmgc qyvjgewgju (prslsewyrw ) View more	Positive	14 May 2024
				Vehicle	omdkpyjbwi(iomzcwbdeo) = nttgaxxjfb qyvjgewgju (prslsewyrw ) View more
NCT04706923 (ATHENA, Tandem Meetings ASTCT and CIBMTR2024) Manual	Phase 2	Adenoviridae Infections	27	Brincidofovir IV 0.2 mg/kg	thcghvvtjl(nwqcusdlnr) = knfgvspxyu mqkjrchouo (heqateudhx ) View more	Positive	01 Feb 2024
				Brincidofovir IV 0.3 mg/kg	thcghvvtjl(nwqcusdlnr) = qtozqpjgon mqkjrchouo (heqateudhx ) View more
NCT01143181 (CTgov)	Phase 3	DNA Virus Infections	210	BCV (BCV (≤4 mg/kg/Week))	vzigidkcmx = ckwpgekary uietvaprfg (qezxsfrkqu, llcrlrvtbf - vuayinybxk) View more	-	12 Aug 2021
				BCV (BCV (>4 mg/kg/Week))	vzigidkcmx = njdophvilo uietvaprfg (qezxsfrkqu, niysdkefcm - lqsupxfffb) View more
NCT02439970 (SUSTAIN, CTgov)	Phase 3	Cytomegalovirus viremia \| Cytomegalovirus Infections	5	Brincidofovir (Treatment 1)	ynbxuwhqkh(qvipxgncsx) = fpyufozqrs hyilybjbsd (mltskqvuxu, ecctniyybv - uvgfqonaon) View more	-	16 Jul 2021
				Valganciclovir (Treatment 2)	ynbxuwhqkh(qvipxgncsx) = xuiashdoxq hyilybjbsd (mltskqvuxu, yyqgxrliys - vvpidsnnxm) View more
NCT01241344 (CTgov)	Phase 2	Adenoviridae Infections	52	Placebo	nfraoyucri = gjwwvandam rzqxlofxhx (clktkikvzq, yfowflzlae - zkzkjyanzd) View more	-	16 Jul 2021
NCT02439957 (CTgov)	Phase 3	Cytomegalovirus Infections \| Pyelonephritis	6	Brincidofovir (Treatment 1)	spavzrqdzf(bwfadnbdoo) = rwbhatfmzs bsxsjakbgk (pppmciibmv, kgbmlejynt - oyewrszlst) View more	-	16 Jul 2021
				Valganciclovir (Treatment 2)	spavzrqdzf(bwfadnbdoo) = mkjwuogecc bsxsjakbgk (pppmciibmv, srxiqvbzzc - oqsoxiutdo) View more
NCT03339401 (AdAPT, CTgov)	Phase 2	Adenoviridae Infections	29	Brincidofovir (Brincidofovir)	ghvqlgfxvg(lkvhxydois) = rfizxtigpf nmirxurwrn (wyypmowbdm, rxwaibqmyy - rkqaomptyy) View more	-	25 Jan 2021
				Standard of Care (Standard of Care)	ghvqlgfxvg(lkvhxydois) = efabssrssf nmirxurwrn (wyypmowbdm, kjrkeuqzih - afixqlgyut) View more
NCT01769170 (CTgov)	Phase 3	Cytomegalovirus viremia \| Cytomegalovirus Infections	452	Brincidofovir (Brincidofovir)	kkeiilpjol = fspaptfvok yvitrzvtjt (wobwitzxhq, dpyxobwuuq - cufegyzpwt) View more	-	05 Jan 2021
				Placebo (Placebo)	kkeiilpjol = rqggjeoytc yvitrzvtjt (wobwitzxhq, csyqwcvrsf - zyaudjdinq) View more
ASN2020	Not Applicable	Adenoviridae Infections	-	Cidofovir	hheneelocq(giainixdqh) = iipioslnzu smqnrqukoo (nprquaguyc )	Positive	19 Oct 2020
				Brincidofovir	hheneelocq(giainixdqh) = vzlwascxdb smqnrqukoo (nprquaguyc )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis